论文部分内容阅读
目的:分析影响干扰素-α(IFN-α)治疗慢性乙型肝炎(CHB)疗效的因素。方法:选择2006年到2009年青岛市传染病医院住院的CHB患者46例,应用IFN-α治疗48周,根据IFN-α治疗的疗效将其分为应答组与无应答组,评价患者的宿主、病毒载量及生化指标等因素对疗效的影响。结果:两组间的性别比例、年龄和病程无显著差异(P>0.05),应答组治疗前HBV-DNA载量低于无应答组,ALT水平高于无应答组,HBeAg阳性患者的应答率高于HBeAg阴性患者,差异均具有统计学意义(P<0.05),应答组在治疗12周时HBV-DNA载量下降>2log的比例高于无应答组,差异具有统计学意义(P<0.05)。结论:治疗前HBVDNA载量低、ALT水平高和HBeAg阳性以及治疗12周时的HBVDNA应答可以作为干扰素-α治疗慢性乙型肝炎48周时应答的预测因素。
Objective: To analyze the factors influencing the curative effect of interferon-α (IFN-α) on chronic hepatitis B (CHB). Methods: Forty-six CHB patients hospitalized in Qingdao Infectious Disease Hospital from 2006 to 2009 were enrolled in this study. The patients were divided into two groups: response group and non-response group according to the curative effect of IFN-α therapy. , Viral load and biochemical indicators and other factors on the efficacy. Results: There was no significant difference in sex ratio, age and course of disease between the two groups (P> 0.05). The HBV-DNA load of response group before treatment was lower than that of non-response group, ALT level was higher than that of non-response group, HBeAg-positive rate The difference was statistically significant (P <0.05), and the ratio of HBV DNA load drop> 2log in response group was higher than that in non-response group at 12 weeks of treatment (P <0.05) ). Conclusions: Pretreatment HBVDNA load is low, ALT level and HBeAg positive and HBVDNA response at 12 weeks can be used as a predictor of interferon-α in response to chronic hepatitis B 48 weeks.